New combo aims to control CLL in just one year

NCT ID NCT06333262

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a one-year treatment plan using two drugs, pirtobrutinib and obinutuzumab, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment before. The goal is to see if this fixed-duration therapy can control the disease effectively. About 60 participants will receive the combination over 12 cycles.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beth Israel Deaconess Medical Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact

    Contact

  • Brigham & Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact

    Contact

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • New England Cancer Specialists

    RECRUITING

    Scarborough, Maine, 04074, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact